3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Tumor-Agnostic
6
Breast
6
Gynecologic
2
CNS
2
Sarcoma
1
Plasma cell
1
Lymphoid
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Conditions
Endometrial Neoplasms
10
Ovarian Neoplasms
7
Breast Neoplasms
4
Neoplasms
2
Fallopian Tube Neoplasms
2
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrent Ovarian High Grade Serous Adenocarcinoma
1
Recurrence
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Low Grade Serous Ovarian Carcinoma
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Endometrioid Adenocarcinoma
1
ER+ HER2- Advanced Breast Cancer
1
Cholangiocarcinoma
1
Carcinoma, Ovarian Epithelial
1
Breast Diseases
1
Adenocarcinoma Of Esophagus
1
Interventions
Paclitaxel
28
Carboplatin
28
pembrolizumab
25
Bevacizumab
14
liposomal doxorubicin
12
Cisplatin
11
Gemcitabine
10
Radiotherapy
8
Drug Therapy
8
Cyclophosphamide
8
Blood Specimen Collection
8
Topotecan
7
Nivolumab
7
olaparib
6
Doxorubicin
6
niraparib
5
Therapeutics
5
Dexamethasone
5
pertuzumab
4
pazopanib
4
lenvatinib
4
fludarabine
4
cemiplimab
4
atezolizumab
4
Trastuzumab
4
Surveys and Questionnaires
4
Psychiatric Rehabilitation
4
Polymerase Chain Reaction
4
Fulvestrant
4
Docetaxel
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms
×
abemaciclib
×
Gynecologic
×
Clear all
NCT05768139
2026-05-22
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled
NCT03339843
2024-03-15
MiMe-A
Jules Bordet Institute
Phase 2
Completed
85 enrolled